- Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. (Phase 2: Non-small cell lung cancer (NSCLC) (adenocarcinoma)). - Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. (Note: There is no limit to the number of prior treatment regimens). - Willingness to undergo pretreatment and on-treatment tumor biopsies (must allow for adequate sample of tissue from appropriate site). - Known active CNS metastases and/or carcinomatous meningitis. (Subjects with previously treated brain metastases permitted if stable).
University of Colorado Hospital
Laura Medina, MD
Protocol Number: 21-4329
More information available at ClinicalTrials.gov: NCT03665285
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers